There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum.
Neonatal lesions of the dopamine (DA) system have different behavioral and neurochemical effects than lesions made in adulthood. Previous data from this laboratory have indicated that in the early postnatal period, lesions to the DA system induced by instrastriatal 6-hydroxydopamine (6-OHDA) result in a rapid and permanent loss of striatal D1 binding sites, but D2 receptor binding is unaffected. The length of the postnatal period within which neonatal instrastriatal 6-OHDA administration is effective in modulating D1 receptor binding is not known. To determine when D1 and D2 receptors are vulnerable to lesions of the DA system, we administered 6-OHDA intrastriatally to damage the DA innervation at different ages in the early postnatal period, at day of birth/postnatal day 1 (P0/1), P7 or P15 and examined DA receptor binding at P90 with quantitative autoradiography. Using [3H]mazindol binding to DA transporters (DAT) to verify the extent of the lesion, we then quantified the number of D1 binding sites using [3H]SCH23390 and D2 sites with [3H]spiroperidol. There were significant reductions in DAT sites at P0/1 (78 to 88%) and P7 (67 to 81%) but less significant changes at P15 (34 to 50% losses). The lesions were most effective for the dorsal caudate-putamen than more ventrally or in the nucleus accumbens. Our results demonstrate a significant reduction in D1 sites in all regions of the neostriatum following lesions at P0/1. The dorsal caudate-putamen was affected the most (51% loss, and the nucleus accumbens (41%) and ventral caudate-putamen less so (31%). No significant changes in D1 receptors were found at P7 or P15 and D2 receptors were unaffected with lesions in any of the age groups. The results indicate that there is a critical period for affecting expression of D1 receptors and this effect may, in addition, be related to the pattern of DA loss. Additionally, regulation of D2 receptors by this degree of loss of DA innervation does not occur during the first two weeks postnatally.
Thomas
W S
WS
Huntsman Cancer Institute, University of Utah, Department of Oncological Sciences, Salt Lake City, UT 84112, USA.
Neal-Beliveau
B S
BS
Joyce
J N
JN
D000375:Aging / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development / Q000378:metabolism*; D001552:Benzazepines / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists / Q000378:metabolism; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors / Q000378:metabolism; D008454:Mazindol / Q000378:metabolism; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D016627:Oxidopamine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D013134:Spiperone / Q000378:metabolism
D001552:Benzazepines; D002352:Carrier Proteins; D018492:Dopamine Antagonists; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C493216:Slc6a3 protein, rat; D013134:Spiperone; D016627:Oxidopamine; D008454:Mazindol; D004298:Dopamine